News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2018

November

Media Release / Nov 01, 2018

Novartis receives Health Canada approval for the combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma

Read More